Rep. Gilbert Ray Cisneros, Jr. Buys BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). In a filing disclosed on December 15th, the Representative disclosed that they had bought between $1,001 and $15,000 in BioCryst Pharmaceuticals stock on November 13th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Spotify Technology (NYSE:SPOT) on 11/26/2025.
• Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 11/26/2025.
• Purchased $1,001 – $15,000 in shares of First Watch Restaurant Group (NASDAQ:FWRG) on 11/26/2025.
• Purchased $1,001 – $15,000 in shares of TKO Group (NYSE:TKO) on 11/26/2025.
• Sold $1,001 – $15,000 in shares of RBC Bearings (NYSE:RBC) on 11/24/2025.
• Sold $1,001 – $15,000 in shares of Stifel Financial (NYSE:SF) on 11/24/2025.
• Purchased $1,001 – $15,000 in shares of Logan Energy (CVE:LGN) on 11/24/2025.
• Sold $1,001 – $15,000 in shares of Primoris Services (NASDAQ:PRIM) on 11/24/2025.
• Purchased $15,001 – $50,000 in shares of LandBridge (NYSE:LB) on 11/21/2025.
• Purchased $50,001 – $100,000 in shares of LandBridge (NYSE:LB) on 11/20/2025.

BioCryst Pharmaceuticals Price Performance

NASDAQ BCRX traded up $0.12 on Friday, reaching $7.41. The stock had a trading volume of 6,235,789 shares, compared to its average volume of 3,895,229. The company has a market cap of $1.56 billion, a P/E ratio of -148.20, a price-to-earnings-growth ratio of 0.70 and a beta of 0.91. The firm has a fifty day moving average of $7.17 and a two-hundred day moving average of $8.14. BioCryst Pharmaceuticals, Inc. has a 1-year low of $6.00 and a 1-year high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Monday, November 3rd. The biotechnology company reported $0.06 earnings per share for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.01). BioCryst Pharmaceuticals had a negative return on equity of 4.24% and a negative net margin of 1.46%.The firm had revenue of $159.40 million for the quarter, compared to analyst estimates of $162.91 million. During the same period in the prior year, the business posted ($0.07) EPS. The firm’s quarterly revenue was up 36.1% compared to the same quarter last year. Research analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

BCRX has been the topic of a number of analyst reports. Evercore ISI restated an “in-line” rating and set a $8.00 target price on shares of BioCryst Pharmaceuticals in a research report on Wednesday, October 1st. JMP Securities boosted their price objective on shares of BioCryst Pharmaceuticals from $17.00 to $27.00 and gave the company a “market outperform” rating in a research report on Wednesday, October 15th. Cantor Fitzgerald raised their target price on BioCryst Pharmaceuticals from $24.00 to $26.00 and gave the company an “overweight” rating in a report on Wednesday, October 15th. TD Cowen started coverage on BioCryst Pharmaceuticals in a report on Wednesday, October 15th. They set a “buy” rating and a $30.00 price target for the company. Finally, Needham & Company LLC reduced their price objective on BioCryst Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, November 4th. Ten research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, BioCryst Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $19.50.

Insider Buying and Selling at BioCryst Pharmaceuticals

In related news, insider Alane P. Barnes sold 19,770 shares of the business’s stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $7.65, for a total transaction of $151,240.50. Following the transaction, the insider owned 345,476 shares in the company, valued at $2,642,891.40. The trade was a 5.41% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last three months, insiders have sold 161,680 shares of company stock valued at $1,164,401. Insiders own 5.10% of the company’s stock.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Several large investors have recently modified their holdings of BCRX. Universal Beteiligungs und Servicegesellschaft mbH boosted its position in BioCryst Pharmaceuticals by 7.7% during the second quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 17,992 shares of the biotechnology company’s stock valued at $161,000 after acquiring an additional 1,288 shares during the last quarter. Royal Bank of Canada grew its stake in BioCryst Pharmaceuticals by 2.4% during the first quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock worth $476,000 after purchasing an additional 1,458 shares during the period. Captrust Financial Advisors increased its holdings in BioCryst Pharmaceuticals by 7.4% in the second quarter. Captrust Financial Advisors now owns 22,105 shares of the biotechnology company’s stock worth $198,000 after purchasing an additional 1,527 shares in the last quarter. Main Management ETF Advisors LLC lifted its stake in BioCryst Pharmaceuticals by 1.7% in the second quarter. Main Management ETF Advisors LLC now owns 112,128 shares of the biotechnology company’s stock valued at $1,005,000 after buying an additional 1,824 shares during the period. Finally, Creative Planning boosted its holdings in shares of BioCryst Pharmaceuticals by 2.6% during the 3rd quarter. Creative Planning now owns 88,477 shares of the biotechnology company’s stock worth $672,000 after buying an additional 2,280 shares in the last quarter. 85.88% of the stock is currently owned by institutional investors and hedge funds.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.